

THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS
INC., and MYLAN INC.

Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB,
INCORPORATED, and BAUSCH & LOMB PHARMA HOLDINGS CORP.

Patent Owners

Case IPR2015-00903

Patent 8,129,431

DECLARATION OF JOHN C. JAROSZ

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
A.	Assignment.....	1
B.	Qualifications	2
C.	Compensation.....	4
D.	Evidence Considered	4
E.	Summary of Opinions	5
II.	BACKGROUND.....	7
A.	Parties to the <i>Inter Partes</i> Review	7
1.	Senju	7
2.	Bausch & Lomb.....	8
3.	InnoPharma.....	9
4.	Mylan.....	10
B.	Cataract Treatments	11
C.	Post-Surgery Options	12
1.	Non-Bromfenac NSAIDs	13
a.	Diclofenac Sodium.....	13
b.	Ketorolac Tromethamine.....	14
c.	Nepafenac.....	14
2.	Corticosteroids.....	15
D.	Prolensa®.....	17
1.	Earlier Bromfenac Products.....	17
2.	ISTA’s Acquisition by Bausch & Lomb	19
3.	Development and Launch of Prolensa®.....	19
E.	Patented Technology.....	20
III.	FRAMEWORK OF ANALYSIS	22
IV.	COMMERCIAL SUCCESS OF THE ’431 PATENT.....	24
A.	Marketplace Success	24
1.	Absolute Performance of Prolensa®	24
2.	Relative Performance of Prolensa®	26
a.	Initially	26
b.	Over Time.....	28

;

c.	Third-Party Perceptions.....	30
d.	Licensing Activity	32
B.	Causal Nexus.....	34
1.	Benefits of the Patented Inventions	34
a.	Clinical Importance of the Benefits	36
b.	Marketing Importance of the Benefits	42
i.	Healthcare Professionals.....	42
ii.	Other Audiences.....	45
c.	Third-Party Perceptions.....	46
2.	Promotional Activities	48
a.	Informative and Persuasive Advertising	48
b.	Pharmaceutical Demand Factors.....	50
i.	Impact of Product Characteristics.....	50
ii.	Impact of Product Quality.....	52
c.	Impact of Promotional Efforts	54
d.	Impact of Price	55
3.	Promotional Spending	58
V.	CONCLUSION	61

I, John C. Jarosz, do hereby declare, under penalty of perjury, as follows.

I. INTRODUCTION

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

A. Assignment

2. I have been retained as an expert on behalf of Bausch & Lomb Incorporated, Bausch & Lomb Pharma Holdings Corp. (collectively, “Bausch & Lomb”) and Senju Pharmaceutical Co. Ltd. (“Senju”) (collectively, with Bausch & Lomb, “Patent Owners”) in connection with the above captioned *inter partes* review (“IPR”) proceeding before the United States Patent and Trademark Office Patent Trial and Appeal Board (“PTAB”).

3. I understand that the PTAB has granted the petition of InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC (collectively, “InnoPharma”), Mylan Pharmaceuticals Inc., and Mylan Inc. (collectively, “Mylan”) (collectively, with InnoPharma, “Petitioners”) to institute an IPR regarding claims 1-22 of U.S. Patent No. 8,129,431 (the “431 patent”) on obviousness grounds. That IPR was assigned Case IPR2015-00903.

4. I understand that the PTAB has granted the petition of the Petitioners

to institute a separate IPR regarding claims 1-30 of U.S. Patent No. 8,669,290 (the “’290 patent”) on obviousness grounds. That IPR was assigned Case IPR2015-00902.

5. I understand that Senju is the assignee of the ’431 patent and that Shirou Sawa and Shuhei Fujita are the named inventors of the patent.
6. I understand that the ’431 patent describes and claims compositions of the active ingredient bromfenac sodium (“bromfenac”) and the surfactant tyloxapol.¹ I further understand that Prolensa® embodies the compositions disclosed in the ’431 patent.
7. I have been asked by Counsel for Patent Owners to assess whether Prolensa® has been a marketplace success, and whether such success is attributable to the inventions claimed in the ’431 patent.

B. Qualifications

8. I am a Managing Principal of Analysis Group, Inc. (“Analysis Group”) and Director of the firm’s Washington, DC office. Analysis Group is an economic, financial, and strategy consulting firm with offices in Beijing, China; Boston, MA; Chicago, IL; Dallas, TX; Denver, CO; Los Angeles, CA; Menlo Park, CA; Montreal, Quebec; New York, NY; San

¹ I understand that a surfactant is a substance that, when added to a liquid, reduces the surface tension of that liquid.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.